Literature DB >> 9526197

Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model.

B R Roos1, M R van Cleeff, W A Githui, L Kivihya-Ndugga, J A Odhiambo, D K Kibuga, P R Klatser.   

Abstract

SETTING: A major out-patient tuberculosis clinic in Nairobi, Kenya.
OBJECTIVE: To ascertain the cost-effectiveness of the polymerase chain reaction (PCR) for the diagnosis of tuberculosis in an urban setting in a developing country.
DESIGN: A cost-effectiveness analysis of PCR and direct smear microscopy examination based on theoretical modelling. The cost-effectiveness was expressed in costs per correctly diagnosed tuberculosis patient for each of the two diagnostic techniques. Data were obtained from the literature, from the staff and the register at the health facility and from structured interviews with patients. Assumptions were made when no data were available.
RESULTS: The PCR is expected to be more specific and sensitive than the routine procedure for diagnosis, but it is also more costly. The routine procedure based on direct smear microscopy turned out to be 1.8 times as cost-effective as PCR.
CONCLUSION: It is concluded that the PCR method can potentially be a cost-effective screening procedure for tuberculosis, provided that the largest contributing cost component, the costs of the PCR-kit, can be reduced substantially.

Entities:  

Mesh:

Year:  1998        PMID: 9526197

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Comparison of PCR with the routine procedure for diagnosis of tuberculosis in a population with high prevalences of tuberculosis and human immunodeficiency virus.

Authors:  Lydia Kivihya-Ndugga; Maarten van Cleeff; Ernest Juma; Joseph Kimwomi; Willie Githui; Linda Oskam; Anja Schuitema; Dick van Soolingen; Lucy Nganga; Daniel Kibuga; Joseph Odhiambo; Paul Klatser
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis.

Authors:  Luciene C Scherer; Rosa D Sperhacke; Antonio Ruffino-Netto; Maria Lr Rossetti; Claudia Vater; Paul Klatser; Afrânio L Kritski
Journal:  BMC Infect Dis       Date:  2009-12-31       Impact factor: 3.090

3.  Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.

Authors:  Chia-Lin Tseng; Olivia Oxlade; Dick Menzies; Anne Aspler; Kevin Schwartzman
Journal:  BMC Public Health       Date:  2011-01-26       Impact factor: 3.295

4.  Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.

Authors:  Anna Vassall; Sanne van Kampen; Hojoon Sohn; Joy S Michael; K R John; Saskia den Boon; J Lucian Davis; Andrew Whitelaw; Mark P Nicol; Maria Tarcela Gler; Anar Khaliqov; Carlos Zamudio; Mark D Perkins; Catharina C Boehme; Frank Cobelens
Journal:  PLoS Med       Date:  2011-11-08       Impact factor: 11.069

5.  Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti.

Authors:  Vary Jacquet; Willy Morose; Kevin Schwartzman; Olivia Oxlade; Graham Barr; Franque Grimard; Dick Menzies
Journal:  BMC Public Health       Date:  2006-08-15       Impact factor: 3.295

6.  Smear plus Detect-TB for a sensitive diagnosis of pulmonary tuberculosis: a cost-effectiveness analysis in an incarcerated population.

Authors:  Karen Barros Schmid; Luciene Scherer; Regina Bones Barcellos; Daniele Kuhleis; Isaías Valente Prestes; Ricardo Ewbank Steffen; Elis Regina Dalla Costa; Maria Lucia Rosa Rossetti
Journal:  BMC Infect Dis       Date:  2014-12-16       Impact factor: 3.090

Review 7.  Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review.

Authors:  T I Armina Padmasawitri; Gerardus W Frederix; Bachti Alisjahbana; Olaf Klungel; Anke M Hövels
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240

8.  A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology.

Authors:  Lucy Cunnama; Gabriela B Gomez; Mariana Siapka; Ben Herzel; Jeremy Hill; Angela Kairu; Carol Levin; Dickson Okello; Willyanne DeCormier Plosky; Inés Garcia Baena; Sedona Sweeney; Anna Vassall; Edina Sinanovic
Journal:  Pharmacoeconomics       Date:  2020-08       Impact factor: 4.981

9.  Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression.

Authors:  Daphne I Ling; Laura L Flores; Lee W Riley; Madhukar Pai
Journal:  PLoS One       Date:  2008-02-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.